Moxifloxacin Eberth (Moxifloxacin)

• Moxifloxacin is a broad‑spectrum fluoroquinolone used to treat bacterial infections in various organ systems.
• Community‑acquired bacterial pneumonia: effective eradication of susceptible pathogens causing lung infection.
• Acute bacterial sinusitis: rapid bacterial clearance in sinus cavities.
• Complicated skin and skin‑structure infections: treatment of severe dermal infections caused by susceptible organisms.
• Complicated intra‑abdominal infections: control of mixed bacterial flora in abdominal cavities.
• Acute exacerbations of chronic bronchitis: reduction of bacterial load during flare‑ups.

• Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. By binding to these enzymes, it prevents the unwinding of bacterial DNA, leading to halted cell division and bacterial cell death. The drug displays concentration‑dependent bactericidal activity against a wide range of Gram‑positive and Gram‑negative organisms.

Moxifloxacin may cause a variety of adverse reactions, ranging from mild to severe.

Common Side Effects

• Nausea or vomiting
• Diarrhea
• Headache
• Dizziness or vertigo
• Rash or mild skin irritation
• Elevated liver enzymes

Serious or Rare Side Effects

• Tendon rupture or tendonitis, especially in the Achilles tendon
• QT interval prolongation leading to cardiac arrhythmias
• Severe hypersensitivity reactions (anaphylaxis, Stevens‑Johnson syndrome)
• Clostridioides difficile‑associated colitis
• Hepatic failure or jaundice
• Peripheral neuropathy

• Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor for adverse events.
• Renal impairment: adjust therapy and monitor renal function.
• Hepatic impairment: use with caution; monitor liver enzymes.
• QT prolongation risk: avoid in patients with known cardiac arrhythmias or electrolyte disturbances.
• Elderly patients: increased susceptibility to tendon injury; advise caution.
• Pregnancy and lactation: safety not established; use only if benefit outweighs risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxifloxacin can interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid)

• Antacids or supplements containing aluminum, magnesium, calcium, or iron: reduce absorption.
• Warfarin: may increase INR and bleeding risk.
• Theophylline: increased plasma concentrations leading to toxicity.
• Cyclosporine: elevated cyclosporine levels.
• Amiodarone or other QT‑prolonging agents: heightened risk of arrhythmias.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of CNS stimulation.
• Oral contraceptives: reduced effectiveness, consider backup method.
• Diabetic agents (e.g., sulfonylureas): potential hypoglycemia.
• Corticosteroids: increased risk of tendon rupture.
• Rifampin: may reduce moxifloxacin plasma levels.